We observed that the enhancement of combined IT with anti-CSF-1R did not cause any significant changes in tumor infiltration with immune cells (CD45+) in both TC-1/A9 and TC-1/dB2m tumors. The gene discussed is PTPRC; the disease is neoplasm.